Articles selected by the Editor
Understanding the Late Outcomes of Drug-eluting Stents
Giora Weisz, MD
Director, Clinical Research, Center for Interventional Vascular Therapy, Columbia University Medical Center; Assistant Professor of Medicine, Columbia University, Cardiovascular Research Foundation
Morphologic Predictors of Drug-eluting Stent Thrombosis
Gaku Nakazawa, MD1, Aloke V Finn, MD and Renu Virmani, MD
1CVPath Institute, Inc.
Articles selected by the Editor
Embolic Protection
Jennifer Franke, MD and Horst Sievert, MD
CardioVascular Center Frankfurt
Guidelines for the Use of Retrievable Vena Cava Filters
John A Kaufman
Professor of Interventional Radiology and Chief of Vascular and Interventional Radiology, Oregon Health & Sciences University/ Dotter Interventional Institute, Portland
Articles selected by the Editor
The Adventitia – The New Frontier in Coronary Atherosclerosis Imaging
Gilles Rioufol1 and Gérard Finet
1Associate Professor of Cardiology at the Interventional Cardiology Department and Reseacher for the French Institute of Health and Medical Research
Plaque Vulnerability and Related Coronary Event Prediction by Virtual Histology
Giuseppe Sangiorgi1, Fabrizio Clementi and Clarissa Cola
1Department of Cardiology, Cardiac Catheterization Laboratory, San Raffaele Hospital, Milan
| Journal Watch |
 |
|
Selected headlines from the top Cardiology journals
Long-Term Clinical Benefit of Sirolimus-Eluting Stents Compared to Bare Metal Stents in the Treatment of Saphenous Vein Graft Disease
The purpose of this study was to evaluate the efficacy of sirolimus-eluting stents (SES) in the treatment of saphenous vein graft (SVG) disease. Journal of Interventional Cardiology Volume 20 Issue 6 Page 458-465, December 2007
|
| Clinical Trial Watch |
|
|
Selected Recrutiing Clinical Trials
SPIRIT V. Post-Marketing Evaluation of the XIENCE™ V Everolimus Eluting Coronary Stent System in Europe
The purpose of this Clinical Evaluation, sponsored by Abbott Vascular, is a continuation in the assessment of the performance of the XIENCE™ V Everolimus Eluting Coronary Stent System (XIENCE™ V EECSS) in the treatment of patients with de novo coronary artery lesions.
|
